Xvivo Perfusion AB (publ) (XVIPF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Xvivo Perfusion AB (publ) (XVIPF) Healthcare & Pipeline Overview

Xvivo Perfusion AB (publ) is a leading medical technology company focused on developing advanced solutions for organ preservation and perfusion, particularly in the transplantation sector, with a robust portfolio including the XVIVO System and STEEN Solution.

What Is the Investment Thesis for XVIPF?

Xvivo Perfusion AB (publ) presents a compelling investment thesis driven by several key value drivers. The company operates in a market projected to grow significantly, with increasing global demand for organ transplants due to rising incidences of organ failure and advancements in medical technology. Xvivo's current market capitalization of $975M and a profit margin of 8.9% reflect its operational efficiency and potential for growth. The company’s gross margin of 65.2% indicates strong pricing power and cost management. Furthermore, the ongoing development of its product pipeline, including the XVIVO System and STEEN Solution, positions Xvivo to capture a larger share of the transplantation market. However, potential risks include regulatory hurdles and competition from other medical technology firms, which could impact adoption rates of Xvivo's innovative solutions. Investors should monitor these factors closely as they evaluate the company's growth potential.

Based on FMP financials and quantitative analysis

XVIPF Key Highlights

Market cap of $975M indicates a solid market presence in the medical technology sector.

• P/E ratio of 113.87 reflects investor expectations for future growth, albeit with high valuation.
• Gross margin of 65.2% showcases strong profitability relative to industry standards.
• Profit margin of 8.9% demonstrates operational efficiency amidst competitive pressures.
• Beta of 1.42 suggests higher volatility compared to the broader market, indicating potential risks.

Who Are XVIPF's Competitors?

XVIPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XVIPF's Key Strengths?

Innovative product offerings that address critical needs in organ transplantation.

• Strong gross margins indicating effective cost management and pricing power.
• Established relationships with transplant centers enhancing market presence.
• Global operational reach allowing for diversified revenue streams.

What Are XVIPF's Weaknesses?

High P/E ratio suggests potential overvaluation relative to earnings.

• Limited product diversification compared to larger competitors.
• Dependence on a niche market may expose the company to sector-specific risks.
• No dividend yield may deter income-focused investors.

What Could Drive XVIPF Stock Higher?

Anticipated regulatory approvals for new product lines aimed at enhancing organ preservation.

• Continued adoption of the XVIVO System by transplant centers globally, driving revenue growth.
• Expansion plans into emerging markets in Asia-Pacific and Latin America.
• Ongoing research and development efforts to innovate and improve existing products.
• Strategic partnerships with healthcare providers to validate and promote Xvivo's technologies.

What Are the Key Risks for XVIPF?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Intense competition from established medical technology firms in the organ preservation sector.
• Regulatory hurdles that may delay product approvals and market expansion.
• Economic fluctuations that could impact healthcare spending and investment in transplantation.
• Changes in healthcare policies affecting funding for organ transplantation initiatives.

What Are the Growth Opportunities for XVIPF?

• Growth opportunity 1: The global organ transplantation market is projected to reach $40 billion by 2028, driven by increasing incidences of organ failure and advancements in transplantation techniques. Xvivo's innovative solutions, particularly in ex-vivo lung perfusion, position the company to capture significant market share as healthcare providers seek to improve transplant outcomes.
• Growth opportunity 2: Expansion into emerging markets, particularly in Asia-Pacific and Latin America, presents a substantial growth avenue for Xvivo. As healthcare infrastructure improves and awareness of organ transplantation increases, the demand for Xvivo's products is expected to rise, potentially increasing revenue streams in these regions.
• Growth opportunity 3: The development of new products and enhancements to existing offerings, such as the XVIVO System and STEEN Solution, can drive future revenue growth. By investing in research and development, Xvivo can maintain its competitive edge and meet the evolving needs of transplant centers worldwide.
• Growth opportunity 4: Strategic partnerships with healthcare institutions and research organizations can facilitate the adoption of Xvivo's technologies. Collaborations aimed at clinical trials and product validation can enhance credibility and drive market penetration, particularly in regions with growing transplant programs.
• Growth opportunity 5: Increasing regulatory support for organ transplantation and preservation technologies can create a favorable environment for Xvivo's growth. As governments and healthcare systems prioritize organ donation and transplantation initiatives, Xvivo's innovative solutions may benefit from enhanced funding and support.

What Are XVIPF's Competitive Advantages?

• Strong focus on innovation and quality, differentiating Xvivo from competitors.
• Established reputation and relationships with transplant centers enhance customer loyalty.
• Proprietary technologies and solutions create barriers to entry for new competitors.
• Expertise in ex-vivo lung perfusion positions Xvivo as a leader in this niche market.
• Global reach and diversified product portfolio mitigate risks associated with market fluctuations.

What Does XVIPF Do?

Founded in 1998 and headquartered in Gothenburg, Sweden, Xvivo Perfusion AB (publ) has established itself as a prominent player in the medical technology sector, specifically in organ preservation and perfusion solutions. The company has developed a suite of innovative products that enhance the viability of organs for transplantation, thereby addressing a critical need in the healthcare system. Among its key offerings are the XVIVO System (XPS), a comprehensive cardiac bypass system designed for normothermic ex vivo lung perfusion (EVLP), and the STEEN Solution, a specialized buffered extracellular solution for perfusing isolated donor lungs. Xvivo's product line also includes the XPS Disposable Lung Kit, Perfadex Plus, and various other devices aimed at improving the transplantation process. With a global reach spanning North America, South America, Europe, the Middle East, Africa, and the Asia Pacific, Xvivo is well-positioned to capitalize on the growing demand for transplantable organs. The company operates in a competitive landscape but differentiates itself through its focus on innovation and quality, which has solidified its reputation among transplant centers worldwide.

What Products and Services Does XVIPF Offer?

• Develops advanced solutions for organ, tissue, and cell preservation in transplantation.
• Offers the XVIVO System (XPS) for normothermic ex vivo lung perfusion (EVLP).
• Provides the STEEN Solution, designed for optimal lung perfusion during transplantation.
• Manufactures various disposable products for lung preservation and perfusion.
• Operates globally, serving markets in North America, Europe, and Asia-Pacific.
• Focuses on innovation to enhance the viability and success rates of organ transplants.

How Does XVIPF Make Money?

• Generates revenue through the sale of medical devices and solutions for organ preservation.
• Offers both integrated systems and disposable products tailored for transplantation needs.
• Engages in partnerships with healthcare institutions for product development and validation.
• Focuses on research and development to innovate and expand its product offerings.
• Targets a global market with a growing demand for organ transplantation solutions.

What Industry Does XVIPF Operate In?

The medical devices industry is experiencing robust growth, driven by technological advancements and increasing healthcare expenditures. The global organ transplantation market is expected to expand significantly, with a growing emphasis on improving organ preservation techniques to enhance transplant success rates. Xvivo Perfusion AB (publ) is strategically positioned within this industry, focusing on innovative solutions that address critical challenges in organ preservation and perfusion. The competitive landscape includes various players, but Xvivo's specialized focus on ex-vivo lung perfusion sets it apart, allowing it to cater to a niche yet vital segment of the healthcare market.

Who Are XVIPF's Key Customers?

• Transplant centers and hospitals specializing in organ transplantation.
• Healthcare providers involved in organ preservation and perfusion.
• Research institutions focusing on transplantation technologies.
• Government and regulatory bodies supporting organ donation initiatives.
• Medical professionals and surgeons involved in transplantation procedures.

Xvivo Perfusion AB (publ) (XVIPF) Valuation Context

Valued at $975M, XVIPF is classified as a small-cap stock. Relative to its peer group, XVIPF's quantitative score of 50/100 is below the peer average of 74/100.

XVIPF Revenue & Earnings Trend

In Q2 2026, XVIPF generated $236.9M in top-line revenue, marking a sequential decrease of 1.7%. The company recorded net income of $16.1M, with diluted EPS of $0.51. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, XVIPF averaged $0.70 in diluted EPS.

Company Profile

Xvivo Perfusion AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Mölndal, SE. The company is led by CEO Christoffer Rosenblad. XVIPF has traded publicly since 2014.

Return on equity for Xvivo Perfusion AB (publ) stands at 4.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. XVIPF trades at a trailing price-to-earnings ratio of 98.16, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.0%, the inverse of the P/E and a quick read on earnings relative to price.

Xvivo Perfusion AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

Xvivo Perfusion AB (publ) has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 0.7% below estimates on average.

Wall Street analysts project Xvivo Perfusion AB (publ) revenue of about $1.00B for fiscal 2026, with EPS near $3.55. The estimate reflects 5 contributing analysts.

XVIPF Financials

XVIPF Latest News

No recent news available for XVIPF.

XVIPF Analyst Consensus

XVIPF MoonshotScore

Xvivo Perfusion AB (publ) Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources